Back to search results

Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound

This study is looking into a new way to help women who have preeclampsia (high blood pressure during or after pregnancy) after they've given birth. Researchers are using a special portable ultrasound device called Butterfly iQ3 to check for extra fluid in the lungs and a major vein (inferior vena cava or IVC). If the ultrasound shows signs of too much fluid, you might receive a medication called oral furosemide or intravenous furosemide (water pills) to help remove the extra fluid. The goal is to see if this approach can help lower blood pressure faster and reduce the number of women who still have high blood pressure when they leave the hospital. This study plans to enroll 96 women aged 18 and older who have had preeclampsia.

Study design
This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 96 women.
What's involved
You would have a point-of-care ultrasound (POCUS) performed by trained staff. If certain results are found, you may receive oral or intravenous furosemide, ordered by your doctor.
Compensation
Not stated in the trial record.
Follow-up
Your blood pressure will be monitored from enrollment through hospital discharge, which is typically 7 days or less.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07167862

Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound

Not Yet Recruiting
PHASE4Ages 18+InterventionalTreatment
University of California, Irvine
~96 participants
Updated 2026-01-23 on ClinicalTrials.gov
What's tested:Butterfly iQ3 ultrasound system for determination of postpartum volume statusOral furosemideIntravenous furosemide

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of subjects with persistent hypertension at time of postpartum hospital discharge
Measured over From study enrollment through completion of study participation, an average of 7 days or less
+1 more outcome measured

Conditions

Preeclampsia
Preeclampsia Postpartum
Preeclampsia Severe or Mild

Explore related trials

Preeclampsia

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Ashten B Waks, MD, MSPH · PRINCIPAL_INVESTIGATOR · University of California, Irvine

Who to contact

Ashten B Waks, MD, MSPH
[email protected]
714-456-2911
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age greater than or equal to 18 years at the time of delivery
Diagnosis of preeclampsia (without severe features, with severe features, HELLP syndrome, eclampsia) during pregnancy
Gestational age greater than or equal to 20 weeks' gestation at delivery
Delivery at the study institution within the 18-month period prior to implementation of the study's POCUS intervention
Available and complete postpartum clinical data on: Daily blood pressure, diuretic or antihypertensive use, length of postpartum hospital stay, readmission within 30 days of primary hospitalization
Age greater than or equal to 18 years at the time of enrollment
Diagnosis of preeclampsia (without severe features, with severe features, HELLP syndrome, eclampsia) made up until 24 hours postpartum Postpartum and within 24 hours of delivery

Exclusion

Delivery at an outside facility or incomplete postpartum records available for analysis
Documentation of chronic kidney disease (CKD stage 3 or higher); selected because diuresis is more likely to be avoided in this patient population even in the presence of physical exam findings suggesting volume overload.
Documentation of postpartum complications unrelated to preeclampsia that may significantly alter hemodynamics (e.g., sepsis, postpartum hemorrhage); selected because diuresis is more likely to be avoided in this patient population even in the presence of physical exam findings suggesting volume overload.
Pre-existing diagnosis of chronic hypertension; selected because previous studies on furosemide use in patients with postpartum preeclampsia have found a significant reduction in hypertension among patients with newly diagnosed hypertensive disorders of pregnancy, but not among those with pre-gestational hypertension, meaning that inclusion of this population might reduce the magnitude of study effects.
Baseline renal dysfunction with serum creatinine \> 1.1 mg/dL; selected as this laboratory finding has been pre-selected as a safety outcome.
Baseline hypokalemia with serum potassium \< 3.5 mEq/L despite previous repletion with intravenous or oral potassium chloride; selected as this laboratory finding has been pre-selected as a safety outcome.
Known hypersensitivity to furosemide or sulfa drugs; selected because this would preclude exposure to the study medication of interest.
Current use of diuretics for other indications (e.g. heart failure); selected because this may require a furosemide or other diuretic regimen different from that planned for the study intervention.

What this trial measures

  • Proportion of subjects with persistent hypertension at time of postpartum hospital dischargeFrom study enrollment through completion of study participation, an average of 7 days or less

    Persistent hypertension at time of postpartum hospital discharge, defined both as blood pressure \> 140/90 mm Hg according to American College of OB/GYN (ACOG) guidelines and 130/80 mm Hg according to Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-9) guidelines

  • Average days to resolution of hypertensionFrom study enrollment through completion of study participation, an average of 7 days or less

    Days to resolution of hypertension, defined both as blood pressure \< 140/90 mm Hg according to ACOG guidelines and 130/80 mm Hg according to JNC-9 guidelines